Document:

Exhibit 10.14.2

 

FIRST
AMENDMENT TO ASSET PURCHASE AGREEMENT

 

THIS FIRST AMENDMENT TO ASSET PURCHASE
AGREEMENT (this “Amendment”) is entered into on
November     , 2006 by and among IBR-BYR L.L.C., a
Louisiana limited liability company (“IBR BYR”), International
BioResources, L.L.C., a Louisiana limited liability company (the “Parent”),
IBR Plasma Centers, L.L.C., a Louisiana limited liability company (“IBR PC”
and, collectively with IBR BYR and the Parent, the “Acquired Asset Entities”),
Talecris Biotherapeutics Holdings Corp., a Delaware corporation (“Holdings”),
and Talecris Plasma Resources, Inc., a Delaware corporation (the “Buyer”).
The Buyer, Holdings and the Acquired Asset Entities sometimes are referred to
collectively herein as the “Parties.”

 

WHEREAS, the Buyer, Holdings and the Acquired
Asset Entities are parties to that certain Asset Purchase Agreement dated October 31,
2006 (the “Agreement”), pursuant to which, subject to the terms and
conditions of the Agreement, the Buyer has agreed to purchase the Acquired
Assets and assume the Assumed Liabilities from the Acquired Asset Entities and
the Acquired Asset Entities have agreed to sell the Acquired Assets and
transfer the Assumed Liabilities to the Buyer; and

 

WHEREAS, the Parties wish to amend the
Agreement with respect to the matters set forth herein.

 

NOW, THEREFORE, in consideration of the terms
and conditions, premises and the other mutual covenants contained herein, and
other good and valuable consideration, the receipt and sufficiency are hereby
acknowledged, the Parties hereto, intending to be legally bound, hereby agree
as follows:

 

1.                               Definitions. All capitalized terms used but not otherwise defined herein shall
have the meanings given such terms in the Agreement.

 

2.                               Amendment to Exhibit A.

 

(a)                                  As required under Section A.
of Exhibit D of the Agreement, the definition of Target Working
Capital set forth in Exhibit A of the Agreement is hereby amended
and restated in its entirety as follows:

 

“Target Working Capital” means
$11,931,659.

 

(b)                                 Exhibit A
of the Agreement is hereby amended by the addition of the following terms:

 

“Effective
Time” has the meaning set forth in §2(e).

 

“Termination
Date” means November 25, 2006 at 11:59 p.m. (if the Closing
occurs on or prior to November 25, 2006); provided, however, that
Talecris shall have the option, exercisable in its sole discretion, to
extend the Termination Date by up to four consecutive two week periods (i.e.,
until December 9, 2006, December 23, 2006, January 6, 2007 and January 20,
2007)

 

 

upon providing five days written notice to
IBR prior to the then current Termination Date.

 

3.                               Amendment to Section 2(c)(i). The first sentence of Section 2(c)(i) of
the Agreement is hereby amended and restated in its entirety as follows:

 

At Closing, the
Buyer shall pay the Acquired Asset Entities the Preliminary Closing Cash
Payment, to be paid in the following order and priority:  (A) first, to General Electric Capital
Corporation to pay off Indebtedness owed or owing to it in the amount set forth
in the applicable Payoff Letter (as defined below) and sufficient to secure the
release of any Security Interests of General Electric Capital Corporation in
the Acquired Assets; (B) then, to each of APC Holdings, Inc. (an
affiliate of Aventis Bio Services, Inc.), Haemonetics Corporation, St.
Martin Bank and Trust Company, Greg Strategier, Robert Gagnard, Oscar Davis, La
Savoy Famille, LC, Claus L. Winther and RR Company of America, L.L.C.
(collectively, the “Lenders”), to pay off all Indebtedness owed or owing
to such Lenders by the Acquired Asset Entities in the amounts set forth in the
applicable Payoff Letters; (C) then, to Octapharma AG to pay off
Indebtedness owed or owing to it in the amount set forth in the applicable
Payoff Letter and sufficient to secure the release of any Security Interest of
Octapharma AG in the Acquired Assets; (D) then, to Talecris
Biotherapeutics, Inc. (“Talecris”) or its Affiliates to pay off any
and all Indebtedness and accounts payable owed or owing to Talecris or its
Affiliates (but excluding the aggregate amount of outstanding prepayments made
by Talecris pursuant to Section 2.7 of the Talecris Supply Agreement and
the aggregate amount of all outstanding Advances, if any, made pursuant to
§5(m) below); and (E) then, to the Acquired Asset Entities, the balance of
the Preliminary Closing Cash Payment.

 

4.                               Amendments to Section 2(d)(i), Section 2(d)(iii) and
Exhibit D.
Section 2(d)(i), Section 2(d)(iii) and the last paragraph of Exhibit D
of the Agreement are hereby amended by replacing any and all references to the
phrase “as of the opening of business on the Closing Date” with the phrase “as of the Effective Time.”

 

5.                               Amendment to Section 2(e). Section 2(e) of the Agreement is
hereby amended by adding the following sentence at the end of such section:

 

Except as otherwise set forth herein, the
effective time for the Closing shall be 10:00 p.m., Eastern Standard Time
on the Closing Date (the “Effective Time”).

 

6.                               Conditional Amendment of Section 6(g)(i). If the Closing occurs on or prior to November 25,
2006, Section 6(g)(i) of the Agreement shall be deemed to be amended
and restated in its entirety as follows:

 

(i)                                     Offers of Employment. Effective as of the Termination Date, the
Buyer shall offer at-will employment to all of the employees listed on Exhibit K
(which shall be updated through the Termination Date, subject to the Buyer’s
reasonable approval thereof) who are in good standing on the Termination Date

 

2

 

(each, a “Termination
Date Employee”), contingent upon the Closing, for at least the same rate of
base salary, wages and/or commissions and the same job position in effect
immediately prior to the Termination Date. A Termination Date Employee will
become an employee of the Buyer (a “Transferred Employee”), if at all,
on or as of: (1) the Termination Date, if such Termination Date Employee
is then actively at work; (2) the Termination Date, if such Termination
Date Employee is absent from work on such date due to authorized vacation, jury
duty or other authorized temporary leave of absence and returns to active
employment following the end of the vacation or leave of absence or the
completion of jury duty, as the case may be; or (3) the date such
Termination Date Employee returns to active employment, in the case of a
Termination Date Employee who, on the Termination Date, is absent from work due
to maternity leave, military leave or long term disability with a right to
return to his or her job, and who returns to active employment within the time
required under the original terms and conditions applicable to such absence.
Notwithstanding the foregoing, the Buyer shall not be obligated to hire any
Termination Date Employee who fails to provide the Buyer documentation as
required by applicable federal or state laws in connection with the
commencement of such employment or who fails to pass the Buyer’s pre-employment
background check.

 

7.                               Conditional Amendment of Section 6(g)(ii). If the Closing occurs on or prior to November 25,
2006, the first and second sentences of Section 6(g)(ii) of the
Agreement shall be deemed to be amended and restated in their entirety to read
as follows:

 

Effective as of the
Termination Date, the Acquired Asset Entities shall terminate the employment of
each Transferred Employee. Unless and except to the extent included in the
calculation of Actual Working Capital or as otherwise set forth in this
Agreement, the Buyer shall have no obligation whatsoever to pay all or any part of,
and the Acquired Asset Entities shall remain responsible for the payment of (1) unpaid
salaries, wages, bonuses, incentive compensation, or payroll items accrued
through the Termination Date, (2) any bonuses or other amounts which, as
of the Termination Date, have been earned by Employees as a result of or
arising from the transactions contemplated herein, and (3) any amounts
payable to any Employee terminated prior to the Termination Date.

 

8.                               Conditional Amendment to Sections 6(g)(iii) –
(v). If the Closing occurs
on or prior to November 25, 2006, Sections 6(g)(iii), 6(g)(iv) and
6(g)(vi) of the Agreement shall be deemed to be amended by replacing any
and all references to the terms Closing Date or Closing with the term “Termination
Date.”

 

9.                               Conditional Amendment to Section 6(g). If the Closing occurs on or prior to November 25,
2006, the following new Section 6(g)(vi) shall be deemed to be added
to the Agreement:

 

(vi)                              Employee
Leasing.

 

(A) 
Commencing immediately after the Effective Time and until the Termination Date
(the “Leasing Term”), the Acquired Asset Entities shall provide the
Closing Date Employees (as defined below) to perform services

 

3

 

that are substantially similar to those
services performed by such employees prior to the Closing with respect to the
Acquired Centers (the “Services”), on the Buyer’s behalf. In connection
with their performance of the Services, the Closing Date Employees shall have
such duties, powers and authority as are reasonably prescribed by the Buyer. Except
as otherwise required under §6(g)(vi)(D), the Acquired Asset Entities shall not
take any action that would prevent or limit the Closing Date Employees from
devoting their best efforts, diligence, and abilities and their full attention
to the business and affairs of the Buyer and to the performance of the Services
as directed by the Buyer; provided, however, that
the actions of any Closing Date Employee (other than actions taken pursuant to
an instruction or direction from a Remaining Employee (defined below) or any
member, manager or officer of any Acquired Asset Entity) shall not be imputed
to the Acquired Asset Entities. For purposes of this Agreement, the term “Closing
Date Employees” means all employees of the Acquired Asset Entities who are in
good standing on the Closing Date, except those employees listed on Exhibit M-1
hereto (the “Remaining Employees”).

 

(B)                                Compensation.

 

(1)                                  Salary
Expense. For the Leasing Term, the Buyer shall reimburse the Acquired Asset
Entities for the salary of the Closing Date Employees as specified Exhibit AA
attached hereto, which is the same salary in effect immediately prior to the
Closing Date. Said reimbursement shall occur as provided in §6(g)(vi)(C) below.

 

(2)                                  Closing
Date Employee Benefits. During the Leasing Term, the Acquired Asset
Entities shall continue to provide or otherwise make available to the Closing
Date Employees all benefits and benefit plans provided to the Closing Date
Employees immediately prior to the Closing, including but not limited to health
benefits, vacation, personal time, sick time and other benefits (collectively, “Benefits”).
The Acquired Asset Entities shall instruct the Closing Date Employees to notify
the Buyer of the use of vacation and, to the extent reasonably practicable, personal
days in advance so as to avoid disruption of the Buyer’s operations. The Buyer
shall reimburse the Acquired Asset Entities for the actual costs incurred by
the Acquired Asset Entities for such Benefits provided to the Closing Date
Employees during the Leasing Term.

 

(3)                                  Travel,
Lodging and Other Expenses. The Closing Date Employees shall be entitled to
reimbursement by the Acquired Asset Entities for all reasonable expenses
incurred in performing the Services in accordance with the Acquired Asset Entities’
standard employee reimbursement policies in effect as of the Closing Date. The
Buyer shall reimburse the Acquired Asset Entities, in accordance with §6(g)(vi)(C) below,
for all such reimbursements paid by the Acquired Asset Entities to the Closing Date
Employees during the Leasing Term.

 

(4)                                  Closing
Date Employee Status. At all times during the Leasing Term, the Closing
Date Employees shall remain employees of

 

4

 

the Acquired Asset Entities. Notwithstanding
their status as employees of the Acquired Asset Entities, these individuals
shall receive instructions and directions from the Buyer and shall report to
the Buyer’s management while performing the Services on behalf of the Buyer. The
Acquired Asset Entities agree to provide for the timely payment of employee
wages and the proper administration and payment of all applicable payroll
taxes, workers’ compensation, group health insurance premiums and other
employee benefit costs in compliance with state and federal law and any
applicable benefit plan requirements.

 

(C)                                Payments.
For each payroll period (or portion thereof) during the Leasing Term, the
Acquired Asset Entities shall furnish the Buyer with a good faith estimate of
all costs and expenses for which the Buyer would be obligated to reimburse the
Acquired Asset Entities under this §6(g)(vi) (collectively, the “Reimbursable
Expenses”) at least two Business Days prior to the day on which payroll is
due to the Acquired Asset Entities’ payroll service provider for such period
(or portion thereof) (each, a “Payroll Due Date”). On or before noon on
the Payroll Due Date, the Buyer shall pay such estimated amount to the Acquired
Asset Entities. Within five Business Days after the end of each such payroll period,
the Acquired Asset Entities shall furnish the Buyer with an invoice setting
forth the actual amount of all Reimbursable Expenses for such payroll period,
together with all supporting documentation. If the actual Reimbursable Expenses
are greater than estimated Reimbursable Expenses, then the Buyer shall pay the
amount of such difference to the Acquired Asset Entities in immediately
available funds in accordance with the Acquired Asset Entities’ written wire
instructions, or if the estimated Reimbursable Expenses are greater than actual
Reimbursable Expenses, the Acquired Asset Entities shall jointly and severally
pay the amount of such difference to the Buyer in immediately available funds
pursuant to the Buyer’s written wire instructions. The Parties will negotiate
in good faith to resolve any disagreements over the amount of actual
Reimbursable Expenses for a period of five Business Days following delivery of
such invoice. The Acquired Asset Entities shall not have any obligation to pay
any of the compensation contemplated in §6(g)(vi)(B) to the Closing Date
Employees unless the applicable payment if first received by the Buyer as
provided for in this §6(g)(vi)(C)

 

(D)                               Misconduct.
The Buyer shall have no right to discipline or discharge the Closing Date
Employees during the term of this Agreement. If the Buyer reasonably determines
that a Closing Date Employee has engaged in misconduct (as defined below) and
has so notified the Acquired Asset Entities in writing of such misconduct, the
Acquired Asset Entities will promptly remove the applicable Closing Date
Employee. For purposes of this §6(g)(vi)(D), the term “misconduct” shall mean (i) fraud,
embezzlement or gross insubordination on the part of a Closing Date
Employee, (ii) a material breach of, gross negligence with respect to, or
the willful failure or refusal by a Closing Date Employee to perform and
discharge the duties, responsibilities or obligations reasonably prescribed by
the Buyer, including, without limitation, the duties, responsibilities or
obligations are substantially similar to the those of the Closing Date Employee
prior to the Closing, (iii) criminal activity reasonably determined

 

5

 

by the Buyer to be detrimental to the Buyer,
its business or its operations, (iv) illegal drug use or alcohol abuse by
a Closing Date Employee, or (v) failure to perform duties,
responsibilities and obligations in accordance with the Buyer’s performance
standards and work rules.

 

(E)                                 Liability.
The Closing Date Employees shall work under the direction and supervision of
the Buyer in accordance with the Buyer’s policies and practices. Accordingly,
the Buyer shall be responsible for the acts and omissions of the Closing Date
Employees during the Leasing Term (including any termination of a Closing Date
Employee pursuant to §6(g)(vi)(D) above) committed pursuant to the
direction and supervision of the Buyer, and the Buyer shall indemnify and hold
the Acquired Asset Entities harmless from all liabilities arising from any such
acts or omissions.

 

10.                         Amendment to Exhibit T-2. Exhibit T-2 of the Agreement is
hereby amended by deleting reference to the Lease Agreement for 1200
Camelia Blvd (Suite 203) by and between Benjamin Blanchet (as sublessor)
and Parent, dated as of June 15, 2006.

 

11.                         Amendment to Exhibit Y. Exhibit Y of the Agreement is
hereby amended by deleting the address included thereon for the Flint(2) center
and replacing it with the following address:

 

Flint(2) - 4027 Jennings Road, Flint,
MI  48504

 

12.                         Additional Exhibit.   The
Agreement is hereby amended by the addition of a new Exhibit AA, in
the form attached hereto.

 

13.                         Election of Purchase Option. The Buyer hereby confirms that, pursuant to
Section 6(h) of the Agreement, it has elected the Purchase Option
with respect to the following Affected Centers: 
El Paso (I), El Paso (III), Fort Worth (I), Fort Worth (II), Glendale,
Colorado Springs, Del Rio, Shreveport, Sioux Falls, Augusta, Dayton,
Indianapolis, Raleigh, Springfield (Oregon), Eagle Pass, El Paso (IV) and San
Antonio.

 

14.                         Governing Law. This Amendment shall be governed by and construed in
accordance with the domestic laws of the State of  New York without giving effect to any choice or conflict of
law provision or rule (whether of the State of New York or any other
jurisdiction) that would cause the application of the laws of any jurisdiction
other than the State of New York.

 

15.                         Effectiveness; Incorporation. This Amendment shall be effective upon
execution by the Parties. This Amendment shall amend, and is incorporated into
and made part of, the Agreement. All references to “this Agreement”
contained in the Agreement or otherwise to the Agreement shall be deemed, for
all purposes, to mean the Agreement, as amended hereby. To the extent that any
term or provision of this Amendment is or may be deemed expressly
inconsistent with any term or provision in the Agreement, the terms and
provisions hereof shall control. Except as expressly amended by this Amendment,
all of the terms, conditions and provisions of the Agreement are hereby
ratified and continue unchanged and remain in full force and effect.

 

6

 

16.                         Counterparts. This Amendment may be
executed in one or more counterparts, each of which shall be deemed an original
but all of which together will constitute one and the same instrument.

 

[Remainder of
this page intentionally left blank]

 

7

 

IN WITNESS
WHEREOF, the Parties hereto have executed this Amendment on the date first
above written.

 

 

	
  TALECRIS
  BIOTHERAPEUTICS HOLDINGS CORP.

  	
   

  
	
   

  	
   

  
	
  By:

  	
  /s/ LAWRENCE
  D. STERN

  	
   

  	
   

  
	
  Name:

  	
  Lawrence D.
  Stern

  	
   

  	
   

  
	
  Title:

  	
  Executive
  Chairman

  	
   

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
  TALECRIS
  PLASMA RESOURCES, INC.

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
  By:

  	
  /s/ RANDALL
  A. JONES

  	
   

  	
   

  
	
  Name:

  	
  Randall A.
  Jones

  	
   

  	
   

  
	
  Title:

  	
  Vice
  President

  	
   

  	
   

  
	
   

  	
   

  
	
  IBR-BYR
  L.L.C.

  	
   

  
	
   

  	
   

  
	
  By:

  	
  /s/ RODNEY
  L. SAVOY

  	
   

  	
   

  	
   

  
	
  Name:

  	
  Rodney L.
  Savoy

  	
   

  	
   

  	
   

  
	
  Title:

  	
  CEO

  	
   

  	
   

  	
   

  
	
   

  	
   

  
	
  IBR PLASMA
  CENTERS, L.L.C.

  	
   

  
	
   

  	
   

  
	
  By:

  	
  /s/ RODNEY
  L. SAVOY

  	
   

  	
   

  	
   

  
	
  Name:

  	
  Rodney L.
  Savoy

  	
   

  	
   

  	
   

  
	
  Title:

  	
  CEO

  	
   

  	
   

  	
   

  
	
   

  	
   

  
	
  INTERNATIONAL
  BIORESOURCES, L.L.C.

  	
   

  
	
   

  	
   

  
	
  By:

  	
  /s/ RODNEY
  L. SAVOY

  	
   

  	
   

  	
   

  
	
  Name:

  	
  Rodney L.
  Savoy

  	
   

  	
   

  	
   

  
	
  Title:

  	
  CEOExhibit 10.14.3

 

SECOND AMENDMENT TO ASSET PURCHASE AGREEMENT

 

THIS
SECOND AMENDMENT TO ASSET PURCHASE AGREEMENT (this “Amendment”)
is entered into on June    , 2007 by and among IBR-BYR
L.L.C., a Louisiana limited liability company (“IBR BYR”), International
BioResources, L.L.C., a Louisiana limited liability company (the “Parent”),
IBR Plasma Centers, L.L.C., a Louisiana limited liability company (“IBR PC”
and, collectively with IBR BYR and the Parent, the “Acquired Asset Entities”),
Talecris Biotherapeutics Holdings Corp., a Delaware corporation (“Holdings”),
and Talecris Plasma Resources, Inc., a Delaware corporation (the “Buyer”).
The Buyer, Holdings and the Acquired Asset Entities sometimes are referred to
collectively herein as the “Parties.”

 

WHEREAS, the Buyer,
Holdings and the Acquired Asset Entities are parties to that certain Asset
Purchase Agreement dated October 31, 2006 (as amended, the “Agreement”),
pursuant to which, subject to the terms and conditions of the Agreement, the
Buyer agreed to purchase the Acquired Assets and assume the Assumed Liabilities
from the Acquired Asset Entities and the Acquired Asset Entities agreed to sell
the Acquired Assets and transfer the Assumed Liabilities to the Buyer;

 

WHEREAS, the
Parties entered into that certain First Amendment to the Asset Purchase
Agreement dated November 18, 2006, pursuant to which the Parties amended
certain terms of the Agreement;

 

WHEREAS,
concurrent with the execution of this Amendment, IBR PC, Parent and the Buyer
have entered into the 3 Center Agreement (as defined below) whereby the Buyer
has agreed to purchase the Las Vegas Center (as defined below), the Rockford
Center (as defined below) and the Montgomery Center (as defined below); and

 

WHEREAS, in
connection with the execution of the 3 Center Agreement, the Parties wish to
amend the Agreement with respect to the matters set forth herein.

 

NOW, THEREFORE, in
consideration of the terms and conditions, premises and the other mutual
covenants contained herein, and other good and valuable consideration, the
receipt and sufficiency are hereby acknowledged, the Parties, intending to be
legally bound, hereby agree as follows:

 

1.             Definitions.
All capitalized terms used but not otherwise defined herein shall have the
meanings given such terms in the Agreement.

 

2.             Amendment of
Exhibit A. Exhibit A to the Agreement is hereby amended by the addition of
the following terms in alphabetical order:

 

“Las Vegas Center”
means the plasma donor center located at 1912 Civic Center Drive, Las Vegas,
Nevada.

 

“Montgomery Center”
means the plasma donor center located at 230 Clayton Street, Montgomery,
Alabama.

 

 

“Rockford Center”
means the plasma donor center located at 605 Mulbery Street, Rockford,
Illinois.

 

“3 Center Agreement”
means that certain Asset Purchase Agreement dated June 9 2007, by and among IBR
PC, Parent and the Buyer, whereby the Buyer has agreed to purchase the Las
Vegas Center, the Rockford Center and the Montgomery Center.

 

3.             Amendment of
Section 2(c)(ii). Section 2(c)(ii) of the Agreement is hereby amended by
adding the following sentence at the end of such section:

 

Notwithstanding the
foregoing provisions of this Section 2(c)(ii), concurrent with the execution
and delivery of the 3 Center Agreement, the Validations Payments shall be
accelerated and the Buyer shall deliver all Validation Payments to the Escrow
Agent or the Parent, as applicable, as if the conditions set forth in (A) and
(B) above have been met, in accordance with the payment provisions set forth
above.

 

4.             Amendment of
Section 2(c)(iii). Section 2(c)(iii) of the Agreement is hereby amended and
restated in its entirety as follows:

 

Concurrent with the
execution and delivery of the 3 Center Agreement, the Milestone Payments shall
be accelerated and the Buyer shall pay or issue all Milestone Payments as if
the conditions set forth on Exhibit C have been met.

 

5.             Amendment to
Exhibit M. Exhibit M to the Agreement is hereby amended by removing
from the “Buyer Restricted Area” section of the exhibit and inserting into the “Seller
Restricted Area” section of the exhibit the references to the Las Vegas Center,
the Rockford Center and the Montgomery Center.

 

6.             Settlement of the
Final Closing Cash Payment. The Parties agree to settle all disputes with
respect to the Post-Closing Statement, the Closing Date Balance Sheet, the
Actual Sources & Uses Statement and the calculation of the Actual Working
Capital and the Final Closing Cash Payment (all of which are attached hereto as
Exhibit A) as set forth below. The total payments set forth in this
Section 6, which net a payment from the Acquired Asset Entities to Buyer of
$331,543 minus the amount to be agreed upon by the parties set forth in Section
6.7 below, fully and finally settle and resolve in all respects all disputes
concerning the Post-Closing Statement, and such payments will be paid within 5
days following the date upon which the Parties come to an agreement on the
amount due the Acquired Asset Entities in Section 6.7 below. The following
items are adjusted and the resultant payments or credits are as follows:

 

6.1           As of the
Closing, the actual cash on hand at the Acquired Asset Entities as reflected on
the Closing Date Balance Sheet was $1,255,431, of which only $206,585 was
credited to Buyer. The Parties agree that the Acquired Asset Entities shall pay
to Buyer, or Buyer shall be credited with, the remaining balance of $1,048,846.

 

6.2           The
Parties agree that, as of the Closing, the total payments for outstanding
deferred revenue receivables was $2,076,863, of which Buyer paid to the
Acquired Asset Entities, at Closing, an amount equal to $1,444,050. The Parties
agree that Buyer shall pay to the

 

2

 

Acquired Asset Entities,
or the Acquired Asset Entities shall be credited with, the remaining balance of
$632,813.

 

6.3           Buyer
agrees that it has no claims against the Acquired Asset Entities for the
amounts paid by Buyer with respect to the disputed amount of $682,563 of
accounts payable overdue in excess of thirty days.

 

6.4           Buyer agrees
that it has no claims against the Acquired Asset Entities for the $1,922,027
reduction of cash against the indebtedness of the Acquired Asset Entities as
reflected in an adjustment to the Actual Sources & Uses.

 

6.5           The
Parties agree that Buyer is not and was not obligated to pay the Acquired Asset
Entities an amount equal to $394,005, which amount was improperly credited in
favor of the Acquired Asset Entities in the Actual Sources & Uses.

 

6.6           The
Parties agree that certain other disputed items in the Actual Sources &
Uses shall be settled by a payment from Buyer to the Acquired Asset Entities
of, or the Acquired Asset Entities shall be credited with $84,490.

 

6.7           Following
the Closing, the Acquired Asset Entities paid certain amounts on behalf of Buyer,
including but not limited to employee health insurance, which are calculated by
the Acquired Asset Entities to total $168,311.36. The Acquired Asset Entities
are entitled to a reimbursement of the actual amounts expended. Buyer and the
Acquired Asset Entities will come to an agreement within 30 days hereof on the
actual expenses incurred by the Acquired Asset Entities on behalf of Buyer,
which amounts will be credited to the Acquired Asset Entities.

 

7.             Amendment of
Section 6(j).  Section 6(j) of
the Agreement is hereby amended by adding the following two sentences at the
end of such section:

 

In the event Buyer at its
sole election amends the specifications set forth on Exhibit O with
respect to an Additional Center, Buyer shall be responsible for any additional
costs incurred by the Acquired Asset Entities for the build out and delivery of
such Additional Center only to the extent such additional costs are directly
related to such amendment to the specifications set forth on Exhibit O.
The Parties agree that if and when Buyer approves a Substitute Center to be
substituted for McAllen, Texas as an Additional Center, Buyer shall be
responsible for any costs incurred by the Acquired Asset Entities in connection
with the build out and delivery of such Substitute Center in excess of
$100,000.

 

8.             Development Cost
Holdback. Notwithstanding Section 2(c)(ii) of the Agreement, the Parties
agree that Buyer shall retain one million four hundred thousand dollars
($1,400,000) from the Development Cost Holdback (“Partial Holdback”) as
partial satisfaction of Parent’s obligations under this Section 2(c)(ii) and
the remaining one million six hundred thousand dollars ($1,600,000) of the
Development Cost Holdback shall be delivered to Parent at closing in the form
of Holdings Common Stock as determined and calculated pursuant to the terms of
the Agreement; provided, however, Buyer
reserves all rights and remedies under the Agreement if the amounts finally
determined to be owed by the Acquired Asset Entities to Buyer exceeds the
Partial Holdback and if the amount finally determined to be owed by the
Acquired Asset Entities

 

3

 

to Buyer is less than the
Partial Holdback, Buyer shall promptly pay the difference to Parent pursuant to
the terms of the Agreement.

 

9.             Governing Law.
This Amendment shall be governed by and construed in accordance with the
domestic laws of the State of New York without giving effect to any choice or
conflict of law provision or rule (whether of the State of New York or any
other jurisdiction) that would cause the application of the laws of any
jurisdiction other than the State of New York.

 

10.           Effectiveness;
Incorporation. This Amendment shall be effective upon the execution and
delivery thereof by the Parties. This Amendment shall amend, and is
incorporated into and made part of, the Agreement. All references to “this
Agreement” contained in the Agreement or otherwise to the Agreement shall be
deemed, for all purposes, to mean the Agreement, as amended hereby. To the
extent that any term or provision of this Amendment is or may be deemed
expressly inconsistent with any term or provision in the Agreement, the terms
and provisions hereof shall control. Except as expressly amended by this
Amendment, all of the terms, conditions and provisions of the Agreement are
hereby ratified and continue unchanged and remain in full force and effect.

 

11.           Counterparts.
This Amendment may be executed in one or more counterparts, each of which shall
be deemed an original but all of which together will constitute one and the
same instrument.

 

[Remainder of this
page intentionally left blank]

 

4

 

IN WITNESS WHEREOF, the
Parties hereto have executed this Second Amendment to the Asset Purchase
Agreement on the date first above written.

 

 

	
  TALECRIS
  BIOTHERAPEUTICS HOLDINGS CORP.

  	
   

  	
   

  	
   

  
	
  By: 

  	
  

  /s/ Lawrence D. Stern

  	
   

  	
   

  	
   

  	
  

  
	
  Name: 

  	
  LAWRENCE D. STERN

  	
   

  	
   

  	
   

  	
   

  
	
  Title:

  	
  EXECUTIVE CHAIRMAN

  	
   

  	
   

  	
   

  	
   

  

 

 

	
  TALECRIS
  PLASMA RESOURCES, INC.

  	
   

  	
   

  	
   

  
	
  By: 

  	
  

  

  /s/ Lawrence D. Stern

  	
   

  	
   

  	
   

  	
  

  
	
  Name: 

  	
  LAWRENCE D. STERN

  	
   

  	
   

  	
   

  	
   

  
	
  Title:

  	
  DIRECTOR/AUTHORIZED
  SIGNATORY

  	
   

  	
   

  	
   

  	
   

  

 

 

	
  IBR-BYR
  L.L.C.

  	
   

  	
   

  	
   

  
	
  By: 

  	
  /s/ AUTHORIZED
  SIGNATORY

  	
   

  	
   

  	
   

  	
  

  
	
  Name: 

  	
  Authorized Signatory

  	
   

  	
   

  	
   

  	
   

  
	
  Title:

  	
  CEO

  	
   

  	
   

  	
   

  	
   

  

 

 

	
  IBR
  PLASMA CENTERS, L.L.C.

  	
   

  	
   

  	
   

  
	
  By: 

  	
  /s/ AUTHORIZED
  SIGNATORY

  	
   

  	
   

  	
   

  	
  

  
	
  Name: 

  	
  Authorized Signatory

  	
   

  	
   

  	
   

  	
   

  
	
  Title:

  	
  CEO

  	
   

  	
   

  	
   

  	
   

  

 

 

	
  INTERNATIONAL
  BIORESOURCES, L.L.C.

  	
   

  	
   

  	
   

  
	
  By: 

  	
  /s/ AUTHORIZED
  SIGNATORY

  	
   

  	
   

  	
   

  	
  

  
	
  Name: 

  	
  Authorized Signatory

  	
   

  	
   

  	
   

  	
   

  
	
  Title:

  	
  CEO

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00129-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00129-of-00352.parquet"}]]